Collegium Pharmaceutical Inc. (COLL) Shares Down 3.2%
Collegium Pharmaceutical Inc. (NASDAQ:COLL) shares fell 3.2% during mid-day trading on Thursday . The company traded as low as $11.99 and last traded at $12.00, with a volume of 59,884 shares traded. The stock had previously closed at $12.40.
A number of research firms recently issued reports on COLL. Zacks Investment Research upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, June 28th. Piper Jaffray Cos. restated a “buy” rating and set a $27.00 price target (up previously from $26.00) on shares of Collegium Pharmaceutical in a research note on Thursday, June 23rd. Finally, Needham & Company LLC restated a “buy” rating and set a $30.00 price target (up previously from $28.00) on shares of Collegium Pharmaceutical in a research note on Thursday, May 26th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Collegium Pharmaceutical presently has an average rating of “Buy” and an average price target of $29.25.
The company’s market cap is $282.09 million. The firm’s 50-day moving average is $12.60 and its 200 day moving average is $16.29.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.08. Analysts predict that Collegium Pharmaceutical Inc. will post ($3.25) earnings per share for the current fiscal year.
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.